内质网应激作为慢性疼痛新兴治疗靶点:叙述性综述
本文为叙述性综述,分析临床前研究,探讨内质网应激如何作为中心节点驱动慢性疼痛的发生与进展,并讨论靶向内质网应激的抑制剂及未折叠蛋白反应调节剂治疗难治性慢性疼痛的前景、获益与缺陷。
要点
- 内质网应激可能是触发慢性疼痛多个分子级联反应的中心枢纽。
- 多种内质网应激抑制剂及未折叠蛋白反应调节剂在临床前疼痛模型中显著减轻痛觉过敏。
- 靶向内质网应激影响多个分子网络,或为对甾体、NSAIDs或阿片类药物难治的慢性疼痛提供新策略。
核心结论
- 靶向内质网应激以影响多个分子网络,可能成为对甾体、NSAIDs或阿片类药物难治的慢性疼痛的有吸引力的治疗策略。
- 该新策略或可为阿片类药物危机和公共卫生挑战提供解决方案。
研究设计与样本
- 叙述性综述,批判性分析临床前研究,探讨内质网应激作为慢性疼痛发生与进展的中心节点机制。
主要发现
- 近期临床前研究显示内质网应激可能是触发慢性疼痛多个分子级联反应的中心枢纽。
- 多种内质网应激抑制剂和未折叠蛋白反应调节剂在多个临床前疼痛模型中显著减轻痛觉过敏。
- 这些抑制剂和调节剂已在随机临床试验中测试或获美国食品药品监督管理局批准用于其他慢性疾病。
- 内质网应激在神经退行性疾病、代谢性疾病和癌症中的作用已确立,但其与慢性疼痛的研究仍处于起步阶段。
临床怎么用
- 当前NSAIDs、甾体或阿片类药物对慢性疼痛的疗效 largely 不令人满意,获益不确定或长期副作用严重。
- 常规止痛药虽可通过控制若干功能失调通路缓解疼痛,但可能掩盖其他潜在病理原因,最终加重神经病理和疼痛结局。
局限性
- 内质网应激与慢性疼痛的研究仍处于起步阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic pain is a severely debilitating condition with enormous socioeconomic costs. Current treatment regimens with nonsteroidal anti-inflammatory drugs (NSAIDs), steroids, or opioids have been largely unsatisfactory with uncertain benefits or severe long-term side effects. This is mainly because chronic pain has a multifactorial aetiology. Although conventional pain medications can alleviate pain by keeping several dysfunctional pathways under control, they can mask other underlying pathological causes, ultimately worsening nerve pathologies and pain outcome. Recent preclinical studies have shown that endoplasmic reticulum (ER) stress could be a central hub for triggering multiple molecular cascades involved in the development of chronic pain. Several ER stress inhibitors and unfolded protein response modulators, which have been tested in randomised clinical trials or apprpoved by the US Food and Drug Administration for other chronic diseases, significantly alleviated hyperalgesia in multiple preclinical pain models. Although the role of ER stress in neurodegenerative disorders, metabolic disorders, and cancer has been well established, research on ER stress and chronic pain is still in its infancy. Here, we critically analyse preclinical studies and explore how ER stress can mechanistically act as a central node to drive development and progression of chronic pain. We also discuss therapeutic prospects, benefits, and pitfalls of using ER stress inhibitors and unfolded protein response modulators for managing intractable chronic pain. In the future, targeting ER stress to impact multiple molecular networks might be an attractive therapeutic strategy against chronic pain refractory to steroids, NSAIDs, or opioids. This novel therapeutic strategy could provide solutions for the opioid crisis and public health challenge.
引用
- Kim HS, Lee D, Shen S, et al. Endoplasmic reticular stress as an emerging therapeutic target for chronic pain: a narrative review. Br J Anaesth. 2024. PMID: 38378384. doi:10.1016/j.bja.2024.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。